FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029626877> ?p ?o ?g. }

• W3029626877 abstract "4051 Background: Advanced squamous cell anal carcinoma (advSCAC) is a rare disease with poor prognosis. No standard therapies beyond first line are currently available, yet a promising activity was documented for the anti-EGFR cetuximab (CET) and for anti-PD-1 agents in previous retrospective case series and phase I-II studies, respectively. In experimental models combination of EGFR and PD-L1 blockade was synergistic as PD-L1 blockade led to NK cells activation enhancing cetuximab ADCC. In this trial we aimed to evaluate safety and activity of the anti-PD-L1 avelumab (AVE) alone or in combination with CET in pretreated advSCAC. Methods: This was an open-label, prospective, multicenter randomized phase 2 trial (NCT03944252). Patients (pts) with advSCAC progressed after at least 1 line of treatment were randomized 1:1 to receive either AVE 10 mg/kg (arm A) or AVE + CET 500 mg/sqm (arm B) as bi-weekly regimens. A Simon’s two-stage Mini-Max design was used. The null hypothesis of a true response rate 5% was tested against the one-sided alternative of a true response rate 20% in each arm. Setting type I error at 0.05 and power at 80%, 30 pts per arm had to be randomized. No formal comparison between the two arms was planned. Primary endpoint was overall response rate (ORR); secondary endpoints were Progression-Free Survival (PFS), Overall Survival (OS) and safety. Results: Sixty pts were enrolled, 30 in each arm. All baseline characteristics were well balanced between the two arms. Median age was 63 years; M/F was 19/41; 12 out of 30 pts in each arm had distant metastases; 7 in arm A and 10 in arm B received > 1 previous lines of treatment. At a median follow up of 8.7 months, 3 out of 30 pts in each arm obtained PR (ORR 10%); SD was observed in 12 pts in arm A (40%) and 14 in arm B (47%). Disease control rate was thus 50% in arm A and 57% in arm B. Duration of disease control was 6.1 (95%CI 3.7–11.0) and 6.1 (95%CI 4.1–9.6) months in arm A and B, respectively. Median PFS was 2.1 (95%CI 1.8–4.0) in arm A and 3.9 months (95%CI 2.1–5.6) in arm B. Grade 3-4 adverse events were 13.3% in arm A and 33.3% in arm B: anemia 10% vs 13.3%, fatigue 0 vs 6.7%, skin toxicity 0 vs 6.7%. Treatment interruption due to AE occurred in 3 pts, 1 in arm A and 2 in arm B. Translational analyses will be performed on tissue and blood samples for exploratory purpose. Conclusions: The CARACAS trial was the first clinical study to test dual EGFR and PD-L1 blockade in advSCAC. Both AVE monotherapy and AVE-CET showed promising activity with manageable safety profile. Clinical trial information: NCT03944252 ." @default.
• W3029626877 created "2020-06-05" @default.
• W3029626877 creator A5012044531 @default.
• W3029626877 creator A5012312536 @default.
• W3029626877 creator A5012705655 @default.
• W3029626877 creator A5015390593 @default.
• W3029626877 creator A5015936724 @default.
• W3029626877 creator A5028325185 @default.
• W3029626877 creator A5034035272 @default.
• W3029626877 creator A5034356923 @default.
• W3029626877 creator A5036411818 @default.
• W3029626877 creator A5044033864 @default.
• W3029626877 creator A5045419569 @default.
• W3029626877 creator A5051613962 @default.
• W3029626877 creator A5053974958 @default.
• W3029626877 creator A5056137510 @default.
• W3029626877 creator A5067402699 @default.
• W3029626877 creator A5074726037 @default.
• W3029626877 creator A5079437223 @default.
• W3029626877 creator A5081353003 @default.
• W3029626877 creator A5086579812 @default.
• W3029626877 creator A5087740216 @default.
• W3029626877 date "2020-05-20" @default.
• W3029626877 modified "2023-09-25" @default.
• W3029626877 title "Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study." @default.
• W3029626877 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4051" @default.
• W3029626877 hasPublicationYear "2020" @default.
• W3029626877 type Work @default.
• W3029626877 sameAs 3029626877 @default.
• W3029626877 citedByCount "1" @default.
• W3029626877 countsByYear W30296268772021 @default.
• W3029626877 crossrefType "journal-article" @default.
• W3029626877 hasAuthorship W3029626877A5012044531 @default.
• W3029626877 hasAuthorship W3029626877A5012312536 @default.
• W3029626877 hasAuthorship W3029626877A5012705655 @default.
• W3029626877 hasAuthorship W3029626877A5015390593 @default.
• W3029626877 hasAuthorship W3029626877A5015936724 @default.
• W3029626877 hasAuthorship W3029626877A5028325185 @default.
• W3029626877 hasAuthorship W3029626877A5034035272 @default.
• W3029626877 hasAuthorship W3029626877A5034356923 @default.
• W3029626877 hasAuthorship W3029626877A5036411818 @default.
• W3029626877 hasAuthorship W3029626877A5044033864 @default.
• W3029626877 hasAuthorship W3029626877A5045419569 @default.
• W3029626877 hasAuthorship W3029626877A5051613962 @default.
• W3029626877 hasAuthorship W3029626877A5053974958 @default.
• W3029626877 hasAuthorship W3029626877A5056137510 @default.
• W3029626877 hasAuthorship W3029626877A5067402699 @default.
• W3029626877 hasAuthorship W3029626877A5074726037 @default.
• W3029626877 hasAuthorship W3029626877A5079437223 @default.
• W3029626877 hasAuthorship W3029626877A5081353003 @default.
• W3029626877 hasAuthorship W3029626877A5086579812 @default.
• W3029626877 hasAuthorship W3029626877A5087740216 @default.
• W3029626877 hasConcept C121608353 @default.
• W3029626877 hasConcept C126322002 @default.
• W3029626877 hasConcept C141071460 @default.
• W3029626877 hasConcept C143998085 @default.
• W3029626877 hasConcept C168563851 @default.
• W3029626877 hasConcept C203092338 @default.
• W3029626877 hasConcept C2779998722 @default.
• W3029626877 hasConcept C31760486 @default.
• W3029626877 hasConcept C526805850 @default.
• W3029626877 hasConcept C535046627 @default.
• W3029626877 hasConcept C71924100 @default.
• W3029626877 hasConceptScore W3029626877C121608353 @default.
• W3029626877 hasConceptScore W3029626877C126322002 @default.
• W3029626877 hasConceptScore W3029626877C141071460 @default.
• W3029626877 hasConceptScore W3029626877C143998085 @default.
• W3029626877 hasConceptScore W3029626877C168563851 @default.
• W3029626877 hasConceptScore W3029626877C203092338 @default.
• W3029626877 hasConceptScore W3029626877C2779998722 @default.
• W3029626877 hasConceptScore W3029626877C31760486 @default.
• W3029626877 hasConceptScore W3029626877C526805850 @default.
• W3029626877 hasConceptScore W3029626877C535046627 @default.
• W3029626877 hasConceptScore W3029626877C71924100 @default.
• W3029626877 hasLocation W30296268771 @default.
• W3029626877 hasOpenAccess W3029626877 @default.
• W3029626877 hasPrimaryLocation W30296268771 @default.
• W3029626877 hasRelatedWork W16708841 @default.
• W3029626877 hasRelatedWork W1912601 @default.
• W3029626877 hasRelatedWork W19152528 @default.
• W3029626877 hasRelatedWork W20302269 @default.
• W3029626877 hasRelatedWork W2959605 @default.
• W3029626877 hasRelatedWork W6187537 @default.
• W3029626877 hasRelatedWork W6817586 @default.
• W3029626877 hasRelatedWork W8337555 @default.
• W3029626877 hasRelatedWork W984313 @default.
• W3029626877 hasRelatedWork W14976891 @default.
• W3029626877 isParatext "false" @default.
• W3029626877 isRetracted "false" @default.
• W3029626877 magId "3029626877" @default.
• W3029626877 workType "article" @default.